Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460087 | 1.00 | METAP2 (0.57) | METAP2KCNH2 | |
| SCHEMBL460123 | 0.93 | METAP2 (0.62) | METAP2 | |
| SCHEMBL460122 | 0.93 | METAP2 (0.62) | METAP2 | |
| SCHEMBL16290056 | 0.88 | METAP2 (0.55) | METAP2 | |
| SCHEMBL435938 | 0.88 | METAP2 (0.58) | METAP2 | |
| SCHEMBL13832796 | 0.88 | METAP2 (0.58) | METAP2 | |
| SCHEMBL15130218 | 0.84 | METAP2 (0.54) | METAP2 | |
| SCHEMBL15130216 | 0.84 | METAP2 (0.54) | METAP2 | |
| SCHEMBL14937305 | 0.84 | METAP2 (0.54) | METAP2 | |
| SCHEMBL10284281 | 0.84 | METAP2 (0.54) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839623-B2 | Tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160354338-A1 | TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-9266896-B2 | Tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| EP-2595988-B1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2595988-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-05-16 | — | — | US | disclosed |
| WO-2012012642-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | CES2, DNPEP, METAP2 | METAP2 3/4885KCNH2 3348/4885 |
| US-20160354338-A1 | TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | CES2, DNPEP, METAP2 | METAP2 3/4885KCNH2 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.